CRISPR Therapeutics AG
CRISPR Therapeutics AG (CRSP) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · CRSP · as of Jun 8, 2026
Key Statistics
Explore CRISPR Therapeutics AG Data
crsp stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 38 · Buy rate: 57.9%
The CRSP analyst consensus is Buy, based on ratings from 38 Wall Street analysts over the past 3 months. The average 12-month price target is $64.60, representing +24.61% upside from the current price of $51.84.
Competitors & Peers
crsp competitorsCRSP
ACLX
AKRO
ARWR
CYTK
KRYSStock Performance
Full HistoryAbout CRISPR Therapeutics AG
CRISPR Therapeutics AG a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)…
what is crispr therapeutics ag · crsp stock overview · crispr therapeutics ag company profile · who is crispr therapeutics ag ceo · crsp NASDAQ · crispr therapeutics ag headquarters · crispr therapeutics ag business segments
About Stock Overview & Key Data
CRISPR Therapeutics AG (CRSP) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Oct 19, 2016. As of the latest trading session, CRSP stock price is $51.84, with a market capitalization of $5.0B. The stock has returned +23.16% over the past 12 months and -1.14% year-to-date.
According to 38 Wall Street analysts, the consensus rating for CRISPR Therapeutics AG stock is Buy, with an average 12-month price target of $64.60. In fiscal year 2025, CRISPR Therapeutics AG reported revenue of $3.5M and net income of -$581.6M. For detailed data — including CRISPR Therapeutics AG revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, CRISPR Therapeutics AG (CRSP) stock price is $51.84. The stock is traded on NASDAQ under the ticker symbol CRSP. The 52-week range is $37.02 – $78.48.